157 related articles for article (PubMed ID: 35184187)
1. Are the Patterns of Cytomegalovirus Viral Load Seen After Solid Organ Transplantation Affected by Circadian Rhythm?
Rafferty H; Murray MJ; Tam JCH; Macfarlane A; Smith C; Lumley SF; Atabani S; McKeating JA; Sharma D; Reeves M; Whitmore D; Griffiths P
J Infect Dis; 2022 Aug; 226(2):357-365. PubMed ID: 35184187
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients.
Lisboa LF; Preiksaitis JK; Humar A; Kumar D
Transplantation; 2011 Nov; 92(9):1063-8. PubMed ID: 21878838
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR: comparison with recipients of solid organ transplants.
Panagou E; Zakout G; Keshani J; Smith C; Irish D; Mackinnon S; Kottaridis P; Fielding A; Griffiths PD
Transpl Infect Dis; 2016 Jun; 18(3):405-14. PubMed ID: 27061703
[TBL] [Abstract][Full Text] [Related]
4. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP
JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644
[TBL] [Abstract][Full Text] [Related]
5. Use of Viral Load as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-analysis.
Natori Y; Alghamdi A; Tazari M; Miller V; Husain S; Komatsu T; Griffiths P; Ljungman P; Orchanian-Cheff A; Kumar D; Humar A;
Clin Infect Dis; 2018 Feb; 66(4):617-631. PubMed ID: 29020339
[TBL] [Abstract][Full Text] [Related]
6. Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy.
Martín-Gandul C; Pérez-Romero P; Blanco-Lobo P; Benmarzouk-Hidalgo OJ; Sánchez M; Gentil MA; Bernal C; Sobrino JM; Rodríguez-Hernández MJ; Cordero E;
Transpl Int; 2014 Oct; 27(10):1060-8. PubMed ID: 24964364
[TBL] [Abstract][Full Text] [Related]
7. Impact of Cytomegalovirus Viral Load on Probability of Spontaneous Clearance and Response to Preemptive Therapy in Allogeneic Stem Cell Transplantation Recipients.
Camargo JF; Kimble E; Rosa R; Shimose LA; Bueno MX; Jeyakumar N; Morris MI; Abbo LM; Simkins J; Alencar MC; Benjamin C; Wieder E; Jimenez A; Beitinjaneh A; Goodman M; Byrnes JJ; Lekakis LJ; Pereira D; Komanduri KV
Biol Blood Marrow Transplant; 2018 Apr; 24(4):806-814. PubMed ID: 29217388
[TBL] [Abstract][Full Text] [Related]
8. An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants.
Manuel O; Pang XL; Humar A; Kumar D; Doucette K; Preiksaitis JK
J Infect Dis; 2009 Jun; 199(11):1621-8. PubMed ID: 19385736
[TBL] [Abstract][Full Text] [Related]
9. Preemptive treatment approach to cytomegalovirus (CMV) infection in solid organ transplant patients: relationship between compliance with the guidelines and prevention of CMV morbidity.
Künzle N; Petignat C; Francioli P; Vogel G; Seydoux C; Corpataux JM; Sahli R; Meylan PR
Transpl Infect Dis; 2000 Sep; 2(3):118-26. PubMed ID: 11429022
[TBL] [Abstract][Full Text] [Related]
10. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy.
Brennan DC; Garlock KA; Lippmann BA; Buller RS; Gaudreault-Keener M; Lowell JA; Miller SB; Shenoy S; Howard TK; Storch GA
J Am Soc Nephrol; 1997 Jan; 8(1):118-25. PubMed ID: 9013456
[TBL] [Abstract][Full Text] [Related]
11. Recurrence of CMV Infection and the Effect of Prolonged Antivirals in Organ Transplant Recipients.
Natori Y; Humar A; Husain S; Rotstein C; Renner E; Singer L; Kim SJ; Kumar D
Transplantation; 2017 Jun; 101(6):1449-1454. PubMed ID: 27467535
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.
Selvey LA; Lim WH; Boan P; Swaminathan R; Slimings C; Harrison AE; Chakera A
BMC Infect Dis; 2017 Jul; 17(1):501. PubMed ID: 28716027
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients.
Freeman RB; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Heaton N;
Transplantation; 2004 Dec; 78(12):1765-73. PubMed ID: 15614149
[TBL] [Abstract][Full Text] [Related]
15. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus load at treatment initiation is predictive of time to resolution of viremia and duration of therapy in hematopoietic cell transplant recipients.
Tan SK; Waggoner JJ; Pinsky BA
J Clin Virol; 2015 Aug; 69():179-83. PubMed ID: 26209403
[TBL] [Abstract][Full Text] [Related]
17. [Clinical study of low cytomegalovirus viral load thresholds for preemptive antiviral therapy in hematopoietic cell transplant recipients].
Li L; Wang Y; Yan CH; Huang XJ
Zhonghua Nei Ke Za Zhi; 2018 Mar; 57(3):191-195. PubMed ID: 29518863
[No Abstract] [Full Text] [Related]
18. Factors associated with the development of cytomegalovirus infection following solid organ transplantation.
da Cunha-Bang C; Sørensen SS; Iversen M; Sengeløv H; Hillingsø JG; Rasmussen A; Mortensen SA; Fox ZV; Kirkby NS; Christiansen CB; Lundgren JD
Scand J Infect Dis; 2011 May; 43(5):360-5. PubMed ID: 21306196
[TBL] [Abstract][Full Text] [Related]
19. A pharmacist-driven antimicrobial stewardship intervention targeting cytomegalovirus viremia in ambulatory solid organ transplant recipients.
Wang N; Athans V; Neuner E; Bollinger J; Spinner M; Brizendine K
Transpl Infect Dis; 2018 Dec; 20(6):e12991. PubMed ID: 30184302
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey.
Navarro D; San-Juan R; Manuel O; Giménez E; Fernández-Ruiz M; Hirsch HH; Grossi PA; Aguado JM;
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28859257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
